CD28null pro-atherogenic CD4 T-cells explain the link between CMV infection and an increased risk of Cardiovascular death by Pera Rojas, Alejandra et al.






2018; 8(16): 4509-4519. doi: 10.7150/thno.27428 
Research Paper 
CD28null pro-atherogenic CD4 T-cells explain the link 
between CMV infection and an increased risk of 
cardiovascular death 
Alejandra Pera1,2,, Stefano Caserta3,†, Fabio Albanese1, Pinar Blowers1, George Morrow1, Nadia 
Terrazzini4, Helen E Smith5, Chakravarthi Rajkumar1, Bernhard Reus6, James R Msonda6,7, Murielle 
Verboom8, Michael Hallensleben8, Rainer Blasczyk8, Kevin A Davies1 and Florian Kern1 
 Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, United Kingdom.  1.
 Immunology and allergy GC-01 group Maimonides Biomedicine Institute of Cordoba (IMIBIC), Reina Sofia Hospital, University of Cordoba, Cordoba, 2.
Spain. 
 Department of Global Health and Infectious Diseases, Brighton and Sussex Medical School, Brighton, United Kingdom.  3.
 School of Pharmacy and Biomolecular Sciences, University of Brighton. 4.
 Family Medicine and Primary Care, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore. 5.
 School of Engineering and Informatics, University of Sussex, Brighton, UK. 6.
 University of Malawi, The Polytechnic, Blantyre, Malawi. 7.
 Institute for Transfusion Medicine, Hannover Medical School, Hannover, Germany.  8.
†School of Life Sciences University of Hull, Hull, UK. 
 Corresponding author: Alejandra Pera, PhD, Maimonides Institute for Biomedical Research (IMIBIC), Edificio IMIBIC, avda Menedez Pidal s/n Córdoba, 
Spain 
© Ivyspring International Publisher. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license 
(https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. 
Received: 2018.05.23; Accepted: 2018.07.18; Published: 2018.08.07 
Abstract 
An increased risk of cardiovascular death in Cytomegalovirus (CMV)-infected individuals remains unexplained, 
although it might partly result from the fact that CMV infection is closely associated with the accumulation of 
CD28null T-cells, in particular CD28null CD4 T-cells. These cells can directly damage endothelium and 
precipitate cardiovascular events. However, the current paradigm holds that the accumulation of CD28null 
T-cells is a normal consequence of aging, whereas the link between these T-cell populations and CMV infection 
is explained by the increased prevalence of this infection in older people. Resolving whether CMV infection or 
aging triggers CD28null T-cell expansions is of critical importance because, unlike aging, CMV infection can be 
treated.  
Methods: We used multi-color flow-cytometry, antigen-specific activation assays, and HLA-typing to dissect 
the contributions of CMV infection and aging to the accumulation of CD28null CD4 and CD8 T-cells in CMV+ 
and CMV− individuals aged 19 to 94 years. Linear/logistic regression was used to test the effect of sex, age, 
CMV infection, and HLA-type on CD28null T-cell frequencies.  
Results: The median frequencies of CD28null CD4 T-cells and CD28null CD8 T-cells were >12-fold (p=0.000) 
but only approximately 2-fold higher (p=0.000), respectively, in CMV+ (n=136) compared with CMV− 
individuals (n=106). The effect of CMV infection on these T-cell subsets was confirmed by linear regression. 
Unexpectedly, aging contributed only marginally to an increase in CD28null T-cell frequencies, and only in 
CMV+ individuals. Interestingly, the presence of HLA-DRB1*0301 led to an approximately 9-fold reduction of 
the risk of having CD28null CD4 T-cell expansions (OR=0.108, p=0.003). Over 75% of CMV-reactive CD4 
T-cells were CD28null.  
Conclusion: CMV infection and HLA type are major risk factors for CD28null CD4 T-cell-associated 
cardiovascular pathology. Increased numbers of CD28null CD8 T-cells are also associated with CMV infection, 
but to a lesser extent. Aging, however, makes only a negligible contribution to the expansion of these T-cell 
subsets, and only in the presence of CMV infection. Our results open up new avenues for risk assessment, 
prevention, and treatment. 











A recent publication shows that Cytomegalo-
virus (CMV) infection increases the risk of 
cardiovascular death by over 20% [1] but no specific 
mechanisms explaining this effect were identified. 
CMV infection, however, is notorious for promoting 
large expansions of terminally differentiated effector 
T-cells, including CD4 T-cells. This is particularly 
observable in older people [2, 3]. Moreover, there is 
good evidence that terminally differentiated T-cells 
may cause vascular damage, to the extent that 
therapies specifically targeting T-cells in advanced 
atherosclerosis are being developed [4-7]. Among 
activated CD4 T-cells, cardiologists are particularly 
interested in CD28null CD4 T-cells [8-10]. These 
terminally differentiated effector cells do not express 
CD28, a co-stimulatory receptor molecule, which 
antigen-presenting cells engage during early T-cell 
activation. CD28null CD4 T-cells were initially 
discovered in rheumatoid arthritis (RA) [11-14], but 
later associated with unstable angina and coronary 
artery plaque instability (CAD) [15]. Multiple links 
between these cells and cardiovascular complications 
have since been reported [16-20]. Down-regulation of 
CD28 on CD4 T-cells is thought to be triggered by 
continuous/repetitive antigen exposure [21], which 
could be the result of a persistent viral infection, for 
example with CMV. CD28null CD8 T-cells, which 
frequently express the surface marker, CD57, were 
also mentioned in the context of cardiovascular and 
autoimmune disease but seem to be associated with a 
broader range of conditions [22]. 
CD28null CD4 T-cells accumulate in older people 
and show reduced proliferative capacity among many 
other signs of cellular senescence. Large frequencies 
of these cells are, therefore, primarily attributed to 
normal (immune system) aging [9, 21, 23]. While an 
association of CMV infection with increased numbers 
of CD28null CD4 T-cells was repeatedly reported in the 
literature [10, 23-27], this link is generally considered 
to be indirect and explained by the fact that older 
people are more likely to be CMV infected [23, 28]. 
Nobody has yet studied CD28null CD4 or CD8 T-cells 
in a large enough number of CMV-seronegative 
(CMV−) older people to resolve this issue. However, 
several smaller studies in the fields of autoimmune 
and cardiovascular disease offer some insight. 
Following participant stratification by CMV infection 
status they reported frequencies of CD28null CD4 
T-cells of 5-10% or more in CMV-seropositive (CMV+) 
but not exceeding 1.5% in CMV− participants [29-32]. 
These results suggest that clinically relevant 
expansions of CD28null CD4 T-cells are effectively 
limited to CMV+ individuals, because the frequencies 
of CD28null CD4 T-cells that were associated with 
clinical effects were generally on the order of several 
percent [10, 33].  
It was not the purpose of our work to show that 
CD28null CD4 T-cells are associated with 
cardiovascular (CV) morbidity or mortality, since 
there is overwhelming evidence for this association in 
the literature [8-10]. Instead, we examined the 
frequencies of CD28null CD4 T-cells in n=93 CMV− 
and n=122 CMV+ generally healthy older people and 
a corresponding cohort of young people; CD28null 
CD8 T-cells were evaluated in parallel. Our 
investigation was focused on the intriguing possibility 
that, independently of aging, CMV infection is a major 
risk factor for the expansion of the highly 
pro-atherogenic CD28null CD4 T-cell subset [8, 9]. This 
would help explain the significant effect of CMV 
infection on CV mortality [1] and open up interesting 
new avenues for research, including future 
therapeutic interventions.  
Results  
Frequencies of CD28null CD4 T-cells are an 
order of magnitude higher in CMV+ compared 
to CMV− individuals 
CD4 T-cells were divided into CD28+ and 
CD28− (‘null’) subsets. These were further subdivided 
by their expression of the differentiation marker, 
CD27 [26, 34] (Figure 1A and Figure S1). Frequencies 
of CD28null CD4 T-cells (in percent of CD4 T-cells) 
ranged from barely detectable to 70% and were log10 
transformed for improved visualization and 
normality of data distribution [35]. Across all 
individuals (CMV+ and CMV−), CD28null CD4 T-cell 
frequencies displayed a bimodal distribution (Figure 
1B, top). Plotting CMV− and CMV+ individuals 
separately provided two very similar, near-normal 
distributions (Figure 1B, middle and bottom); 
however, in CMV+ participants the median was 
significantly higher (by a factor of 12.7) (Figure 1C). 
This difference was explained by CD28null CD4 T-cells 
lacking CD27 (p = 0.000). Those expressing CD27 
made no contribution (Figure 1D). ROC analysis 
based on CD28null CD4 T-cell frequencies for 
discriminating CMV− and CMV+ individuals 
revealed an AUC of >0.910 (p=0.000) for all CD28null 
CD4 T-cells (and an even higher AUC for 
CD28nullCD27− CD4 T-cells). Note that a value >1.5% 
of CD28null CD4 T-cells identified a CMV+ individual 
with >95% probability (Figure 1E). 
As no clear definition of ‘T-cell expansion’ exists 
in the literature, in analogy to our own previous work 
[35], we defined expansions of CD28null CD4 T-cells as 
frequencies above a non-parametric, upper outlier 
limit (upper quartile + 1.5×interquartile range). Only 





CMV− people were used as ‘normal’ reference group 
because of the observed effects of CMV infection on 
CD28null CD4 T-cell frequencies (Figure 1B). CD28null 
CD4 T-cell expansions were, therefore, defined as 
frequencies exceeding 2.9% of CD4 T-cells (Figure 1C, 
dotted line). According to this definition, <3% (3/106) 
of CMV− but >55% (76/136) of CMV+ individuals 
had expansions.  
CMV infection is associated with a smaller 
increase of CD28null CD8 T-cells than CD28null 
CD4 T-cells 
Frequencies of CD28null CD8 T-cells (in percent of 
CD8 T-cells) were generally higher in CMV+ 
individuals (Figure 2A). However, unlike for CD28null 
CD4 T-cells, no clear bimodal distribution was visible 
in the whole cohort (Figure 2B, top). Nevertheless, 
separate analysis of CMV− and CMV+ individuals 
revealed an approximately 2.2-fold median difference 
between the two populations (Figure 2B, middle and 
bottom, and Figure 2C). In analogy to CD28null CD4 
T-cells, this difference was explained by the subset 
lacking CD27 expression (p=0.000). Interestingly, the 
subset expressing CD27 was significantly reduced in 
CMV+ individuals (Figure 2D). As with CD28null CD4 
T-cells, ROC analysis provided good discrimination 
between CMV− and CMV+ individuals based on all 
CD28null CD8 T-cells (AUC=0.777; p=0.000) but even 
better discrimination when only CD28nullCD27− CD8 
T-cells were taken into account (Figure 2E). On the 
whole, the overlap between CMV− and CMV+ 
populations was bigger with respect to CD28null CD8 
than CD28null CD4 T-cell frequencies. 
The effect of age on CD28null CD4 and CD8 
T-cells is marginal 
To quantify the effects of CMV infection and age 
on CD28null CD4 T-cell frequencies, we used a 
hierarchical multiple regression model including sex 
as a possible confounder. Models based on sex alone 
or sex and age together explained only 0.2% and 1.8% 
of the variance of CD28null CD4 T-cell frequencies, 
respectively. After adding CMV infection status, the 
model explained 47.8% of that variance. While both 
CMV infection and age had statistically significant 
effects, becoming CMV+ was equivalent to the effect 
of 253 years of aging (Table 1). The corresponding 
model for CD8 T-cells showed an even smaller effect 
of age and a much smaller effect of CMV infection on 
the variance of CD28null CD8 T-cell frequencies, with 
 
Figure 1. CD28null CD4 T-cell numbers are by an order of magnitude higher in CMV+ compared to CMV− people. (A) Dotplots showing CD27/CD28 expression 
on CD4 T-cells in CMV− and CMV+ individuals. CD28null cells are indicated (circle). (B) The CD28null CD4 T-cell frequency distribution (log10-transformed CD4 T-cell fractions) 
is shown for the whole cohort (top, n=242), CMV− (middle, n=106) and CMV+ individuals (bottom, n=136). (C) Scatterplots show log10-transformed fractions of CD28null CD4 
T-cells. The UQ+1.5×IQR for CMV− individuals is indicated (dotted line). (D) Scatterplots show the log10-transformed fractions of the CD27+ and CD27− subsets of CD28null 
CD4 T-cells. Error bars in scatterplots show median, upper, and lower quartiles. (E) The ROC curve shows the separation of CMV− and CMV+ populations by CD28null CD4 T-cell 
frequencies.  
 





only 17.8% of that variance being explained by CMV 
status (Table 2). Without CMV status, the model 
explained only 2.1% of this variance.  
Of note, CD28null CD4 T-cell frequencies were 
not significantly different between young and older 
CMV− individuals, whereas among CMV+ 
individuals a small, statistically significant difference 
between the age groups was observed (Figure 3A). 
The latter corresponded to the small but significant 
effect of aging found in the regression models, which 
take the whole population (CMV− and CMV+) into 
account. The same applied to CD28null CD8 T-cells 
(Figure 3B).  
CRP only has a small effect on CD28null CD4 
T-cell frequencies 
In analogy to a historic study on CMV and CAD 
[36], we compared the frequencies of CD28null CD4 
T-cells between 4 subgroups based on CMV infection 
status (CMV+ or CMV−) and normal versus raised 
CRP levels (≤ 5 mg/L or > 5 mg/L). CRP was 
available in a total of n=210 older participants. The 
highest frequencies of CD28null CD4 T-cells (median) 
were found in CMV+ people with CRP levels > 5 
mg/L (Figure 3C), the same group that was 
previously found to have the highest CAD 
prevalence. However, the difference in CD28null CD4 
T-cells frequencies between CMV+ individuals with 
CRP-levels ≤ 5 mg/L or > 5 mg/L was statistically not 
significant; thus, CRP was clearly not a critical factor 
for their accumulation. The same trend was observed 
for CD28null CD8 T-cells but differences were not 
statistically significant either (not shown).  
 
 
Figure 2. In CMV+ people, CD28null CD8 T-cell numbers are about twice as high as in CMV− people. (A) Dotplots show CD27 versus CD28 expression on CD8 
T-cells in CMV− and CMV+ individuals. CD28null cells are indicated (circle). (B) The CD28null CD8 T-cell frequency distribution (log10-transformed CD8 T-cell fractions) is 
shown in the whole cohort (top, n=242), CMV− (middle, n=106) and CMV+ individuals (bottom, n=136). (C) Scatterplots show log10-transformed fractions of CD28null CD8 
T-cells. (D) Scatterplots show log10-transformed fractions of the CD27+ and CD27− subsets of CD28null CD8 T-cells. Error bars in scatterplots show median, upper, and lower 
quartiles. (E) The ROC curve shows the separation of CMV− and CMV+ populations by CD28null CD8 T-cell frequencies. 
 
Table 1. Effect of CMV infection status, age and sex on the size of the CD28null CD4 T-cell subset.a 
Variable Parameter estimate Standard error 95% CI for parameter t P-value R2 b 
   lower bound upper bound    
Intercept -2.857 0.183 -3.218 -2.497 -15.614 0.000  
47.8% c Sex 0.020 0.069 -0.117 0.156 0.287 0.774 
Age 0.004 0.002 7.168×10-5 0.008 2.005 0.046 
CMV infection  1.012 0.070 0.874 1.149 14.499 0.000 
a The table shows the final step of the hierarchical multiple regression model. 
b Percent variability of dependent variable explained. 
c R2 for models including sex alone or sex and age were 0.2 and 1.8%, respectively. 





Table 2. Effect of CMV infection status, age and sex on the size of the CD28null CD8 T-cell subset.a  
Variable Parameter estimate Standard error 95% CI for parameter t P-value R2 b 
   lower bound upper bound    
Intercept -0.777 0.106 -0.986 -0.567 -7.313 0.000  
17.8% c Sex 0.026 0.040 -0.105 0.054 -0.639 0.524 
Age 0.003 0.001 0.000 0.005 2.102 0.037 
CMV infection  0.273 0.041 0.193 0.352 6.733 0.000 
a The table shows the final step of the hierarchical multiple regression model. 
b Percent variability of dependent variable explained. 
c R2 for models including sex alone or sex and age were 0.1% and 2.1 %, respectively. 
 
 
Figure 3. Effect of age, HLA and CRP on CD28null CD4 T-cells. (A-B) Scatterplots show differences in CD28null CD4 (A) and CD8 (B) T-cell frequencies between young 
and older CMV− and CMV+ people (n.s.= not significant). CD28null T-cell fractions were log10-transformed for better visualization. (C) Box-plots show the levels of CD28null 
CD4 T-cell frequencies in four subgroups based on CMV infection status (CMV− green, CMV+ red) and CRP levels (≤ 5 mg/L or >5mg/L). (D) Bar-charts show significant 
differences in the frequencies of arginine (R), lysine (K), and alanine (A) at positions 71 and 74 of exon 2 of HLA-DRB1 in individuals with and without expansions. Significance 
levels are indicated. 
 
HLA-type significantly affects CD28null CD4 
T-cell expansions  
The frequencies of CD28null CD4 T-cells were 
significantly higher in CMV+ than in CMV− 
participants but varied by about a factor of 1000 in 
both groups, suggesting they were affected by 
additional parameters (Figure 1B). We previously 
observed an effect of HLA type on the frequencies of 
CMV-specific T-cells [35] and now wished to explore 
if this was also true for CD28null CD4 T-cells. Since the 
effect of CMV infection on the CD28null CD8 T-cell 
subset was small and the frequencies of these cells 
were less variable, we focused on CD28null CD4 T-cells 
for the remainder of the analysis.  
Since CD4 T-cells are class-II MHC restricted, 
high-resolution HLA-DRB1 and DQB1 typing was 
performed in a subgroup of 64 CMV+ individuals (no 
materials for HLA-typing were available for the 
remaining participants). We used data reduction 
analysis to identify the most relevant alleles/allele 
groups in regard to CD28null CD4 T-cell frequencies 
and then built a linear regression model including the 
selected alleles/allele groups along with age and sex 
as independent variables (sex was considered to be a 
possible confounder). This model explained 22.8% of 
the variation of CD28null CD4 T-cell frequencies in 
CMV+ individuals, and showed that the effects of 
both age and sex were minor and statistically 
insignificant (Table 3). 





Table 3. Effect of sex, age, and HLA-type on CD28null CD4 T-cell frequencies.a 
Hierarchical multiple regression levels Variables considered P b R2 c 
(1)  Sex  0.136 0.035 (3.5%)  
(2) Sex, Age 0.093 0.075 (7.5%) 
(3) Sex, Age 
DRB1*03:01P, DQB1*02:01P, DQB1*03:02P  
0.009 0.228 (22.8%) 
aHierarchical multiple regression was used to analyze the effect of HLA-type on the frequencies of CD28null CD4 T-cells among CMV+ individuals. 
b Level of significance for the model. 
c Percent variability of dependent variable explained. 
 
Table 4. Arginine in position 74 of HLA-DRB1 protects from CD28null CD4 T-cell expansion. 
Variable Parameter estimate Standard error p-value OR 95% CI for OR Pseudo-R2 (model fit) b 
Sex (m) -1.063 0.640 0.097 0.345 0.098 - 1.211  
age 0.055 0.023 0.019 1.056 1.009 - 1.106  
Arg71 1.748 0.871 0.045 5.742 1.041 - 31.680 0.351 - 0.468 
Arg74 -2.166 0.807 0.007 0.115 0.024 - 0.550  
constant -4.029 1.872 0.031 0.018 n.a.  
a A binary logistic regression model was constructed based on sex (step 1), age (step 2), and Arg71 as well as Arg74 (step 3). The table shows step 3 of the model, which 
provided correct classification in 79.4% of cases. 
b The model fit is shown as the range between Cox & Snell and Nagelkerke pseudo-R2. 
 
The model did not, however, directly answer if 
the presence or absence of certain HLA-alleles/allele 
groups made the occurrence of expansions of CD28null 
CD4 T-cells more or less likely (i.e., frequencies 
exceeding 2.9% of CD4 T-cells, see above). For that 
purpose, we used binary logistic regression where the 
binary outcome was ‘expansion’ or ‘no expansion’. 
The initial binary model was based on the same 
independent HLA variables as the above linear 
model. All models also included age and sex as 
independent variables; HLA variables not making 
significant contributions were removed during model 
optimization. Our optimized model included only 
HLA-DRB1*03:01P, age, and sex. It showed that 
HLA-DRB1*03:01P had a strongly negative effect on 
CD28null CD4 T-cell expansions and provided correct 
classification in 73.4% of cases with a good model fit 
(Table S3). To potentially improve classification, we 
built alternative models (always including age and 
sex) based on the amino acid sequence of the 
HLA-DRB1 binding groove (its exon 2 sequence) 
rather than allele group/allele names. Amino acids in 
certain positions of the binding groove determine if a 
peptide can be presented or not [37], and certain 
combinations of amino acids in positions 11, 71 and 74 
(‘haplotypes’) were previously linked to disease 
severity and, interestingly, cardiovascular events in 
RA (Table S4) [38, 39]. An optimized model based on 
these haplotypes provided correct classification in 
75% of cases and, similar to the effect of 
HLA-DRB1*03:01P in the previous model, the 
haplotype Ser11-Lys71-Arg74 had a strongly negative 
effect on expansion (Table S5). Interestingly, both 
HLA-DRB1*03:01P and Ser11-Lys71-Arg74 are 
associated with a mild course of RA [38, 39]. In our 
cohort, HLA-DRB1*03:01P was the only allele group 
expressing Ser11-Lys71-Arg74, i.e., the models 
confirmed each other. We finally investigated if 
classification could be further improved by directly 
using amino acids in certain positions of exon 2 as 
model variables (rather than the presence/absence of 
set haplotypes). Interestingly, significant differences 
between groups existed with respect to positions 71 
(Lys71, Arg71) and 74 (Ala74, Arg74) but not position 11 
(Figure 3D). Our final, optimized model was based on 
Arg71 and Arg74, and provided correct classification in 
79.7% of cases with an excellent fit (Table 4). Note that 
the effect of age and sex in all models was minor. 
CD28null CD4 T-cell accumulations seem to 
affect blood pressure 
The average number of anti-hypertensives, an 
indirect indicator of the severity of hypertension, was 
significantly higher in participants with CD28null CD4 
T-cell expansions. This was true when beta-blockers 
and diuretics were included (p=0.021) but also when 
they were excluded (p=0.027). Moreover, 45/143 
(31%) of participants without CD28null CD4 T-cell 
expansions but 33/72 (46%) of those with expansions 
were taking one or more anti-hypertensives (p=0.05, 
Chi-square test) when diuretics and beta-blockers 
were included; the figures were 38/143 (27%) and 
30/72 (42%), respectively, when diuretics and 
beta-blockers were excluded (p=0.03, Chi-square test). 
The percentages of participants with previous 
vascular complications (at least one of the following, 
TIA or stroke, coronary graft, or stent) were not 
significantly different between these groups. 
However, individuals with complications had on 
average higher levels of CD28null CD4 T-cells (not 
statistically significant). With respect to lipid profiles 
(total cholesterol, HDL-cholesterol, LDL-cholesterol, 
and triglycerides), no significant differences between 
CMV− and CMV+ individuals (Table S6) or between 





those with and without expansions of CD28null CD4 
T-cells were found (n=56 and n=112, respectively). 
Significant proportions of CD28null CD4 T-cells 
are CMV specific 
To quantify the proportion of CD28null cells 
among CMV-specific CD4 T-cells, PBMC from 7 
CMV+ individuals (Table S7) were stimulated with 
peptide pools, each representing one complete CMV 
protein. CMV-specific CD4 T-cells were identified by 
intracellular IFN-ɣ, TNF, or IL-2; the distributions of 
activated cells into CD28null and CD28+ subsets were 
analyzed with respect to each cytokine (Figure 4). 
IFN-ɣ and TNF-producing CMV-specific CD4 T-cells 
were predominantly CD28null (median >70%). Very 
few cells expressed IL-2 and no significant difference 
between the CD28null and CD28+ subsets was 
observed. Between 3% and 18% (median 7%) of 
CD28null CD4 T-cells responded to single, selected 
CMV peptide pools. In agreement with the literature 
[29], all CD28null CD4 T-cells strongly expressed the 
vascular adhesion marker, CD49d. This was, 
moreover, true for all CMV-specific T-cells (Figure S2 
and Figure S3). 
Methods 
Ethics Statement 
The study was approved by the UK National 
Research Ethics Service (NRES) (09/H1102/84 and 
13/LO/1270). Written informed consent was obtained 
from all participants. The study was conducted in 
agreement with the Declaration of Helsinki. 
 
 
Figure 4. Expression of CD28 by CMV-specific cells. PBMCs from a representative CMV+ individual stimulated with CMV-peptide (UL83). Plots show unstimulated (left) 
and stimulated CD4 T-cells (middle). CD28 expression is shown versus IFN-ɣ (top), TNF (middle), and IL-2 (bottom), each identifying responding cells. SEB stimulation (positive 
control) strongly induced all three cytokines (not shown). Individual scatter graphs (right) show CD28 expression in responding cells (proteins UL55, UL83, or UL86, n=7). At 
least 40% and up to almost 90% (median 70%) of IFN-ɣ and TNF-producing CMV-specific T-cells are CD28null. Error bars show median and interquartile range. 
 





Participants and samples 
Twenty-seven healthy, young volunteers (19–32 
years) were recruited from university (students/ 
staff), 215 generally healthy, older volunteers (60–94 
years) were recruited by general medical 
practitioners. Some of the older volunteers had 
previously experienced vascular events, including 
TIA, stroke, or CV complications treated with 
coronary stent implantation or grafts. Such 
individuals were not excluded if generally well with 
normal physical activity. Individuals with significant 
CV morbidity, however, were excluded (please see 
Supplementary Material for more details).  
CMV serology 
CMV immunoglobulin G (IgG) serology 
(Architect CMV IgG, Abbot, Maidenhead, UK) was 
performed at the Brighton and Sussex University 
Hospital Trust (BSUHT) virology laboratory. 
Whole blood antibody staining for CD28null 
CD4 T-cells 
Fresh whole blood was stained with 
fluorophore-labeled monoclonal antibodies: CD45, 
CD3, CD4, CD8, CD28 and CD27 in a ‘lyse and wash’ 
protocol (see Supplementary Material).  
Additional phenotypic characterization of 
CD28null CD4 T-cells 
Frozen PBMC from 8 old CMV+ individuals 
were used to characterize the expression of CD49d on 
CD28null CD4 T-cells (see Supplementary Material).  
CMV peptides 
CMV proteins for stimulation were chosen based 
on CD4 T-cell responses previously studied in the 
same individuals (see Supplementary Material).  
CMV reactivity of CD28null CD4 T-cells 
PBMCs from CMV+ individuals were activated 
with overlapping peptide pools, stained and acquired 
by flow-cytometry (see Supplementary Material).  
CRP and lipid profiles 
CRP and lipid profiles were determined at the 
Brighton and Sussex University Hospital Trust 
(BSUHT) pathology laboratory (Cobas analyzer 
platform, Roche, Burgess Hill, UK). Non-HDL- 
cholesterol was calculated as ‘total cholesterol – 
HDL-cholesterol’. The LDL/HDL cholesterol ratio 
was calculated as ‘LDL-cholesterol/HDL-cholesterol’. 
HLA-typing and sequence analysis 
HLA-typing was performed at the Institute for 
Transfusion Medicine, Hannover Medical School, 
Hannover/Germany (see Supplementary Material).  
Data acquisition and analysis 
Samples were acquired on an LSR II 
flow-cytometer (BD). FlowJo v9.x software (Tree Star 
Inc., Ashland, OR) was used for data analysis. Gating 
strategies are described in Figure S1-3.  
Statistical analysis 
GraphPad Prism 7 (GraphPad Software, Inc., San 
Diego, California, USA) and SPSS v23/v24 software 
(IBM, London, UK) were used for visualization and 
statistical analysis. Population frequencies were 
log10-transformed to improve normality and 
visualization. Hierarchical/binary logistic regression 
models were run in SPSS. For additional details please 
see Supplementary Material. 
Discussion  
Our results show that CMV infection is 
significantly associated with the accumulation of 
CD28null CD4 T-cells, which are known to trigger 
cardiovascular complications and even stroke [9]. Our 
data further suggest that CMV may directly drive this 
subset with a significant proportion of these cells 
recognizing CMV-antigens. The frequencies of 
CD28null CD4 T-cells were an order of magnitude 
(>12-fold) higher in CMV+ compared to CMV− 
individuals but only marginally affected by age (note 
that in older CMV− individuals, frequencies were 
below 1.5% in >95% of all cases). A small effect of age 
was noted in CMV+ individuals only and might be 
related to the duration of CMV infection. These 
observations seem to refute the idea that 
accumulation of CD28null CD4 T-cells is a result of 
normal (immune-system) aging [40].  
The fact that only CMV-infected people can 
account for high frequencies of CD28null CD4 T-cells 
sheds new light on numerous published reports. For 
illustration, in 2007, Liuzzo et al. [18] reported 
CD28null CD4 T-cell frequencies in 3 patient groups 
with increasing severity of CAD. Thirty-five percent 
of those with the mildest disease displayed CD28null 
CD4 T-cell frequencies >4%. Such frequencies, 
however, were displayed by 50% and 75%, 
respectively, of the groups with greater and the 
greatest severity of CAD. While the CMV infection 
status of these individuals was unknown, our results 
suggest that at least 95% of the individuals with 
CD28null CD4 T-cell frequencies >4% were CMV+. It 
would appear that in Liuzzo’s study, the proportion 
of CMV-infected individuals increased with 
increasing disease severity. Others made similar 
observations regarding high frequencies of CD28null 
CD4 T-cells in cohorts whose CMV infection status 
was unknown [10, 33]. Our results strongly argue that 
these observations reflect CMV-associated 





immunopathology, rather than normal (immune) 
aging [23]. Clearly, CMV infection triggers 
mechanisms that result in the accumulation of 
clinically relevant frequencies of these cells. The 
reason we are reiterating this is that, unlike aging, the 
effects of CMV infection may respond to appropriate 
treatment. Our work might be of particular relevance 
for CVD in the context of autoimmunity, in particular 
RA, where CD28null CD4 T-cell expansions are rife and 
were originally discovered [10]. CVD and 
autoimmunity are strongly associated with each other 
[41], and CMV-driven expansions of CD28null CD4 
T-cells are one plausible link between these 
pathologies [33].  
We also explored the effects of CMV infection 
and age on CD28null CD8 T-cells. As with CD28null 
CD4 T-cells, the frequencies of their CD8 counterparts 
were only marginally affected by age and any such 
effect was limited to CMV+ individuals. As a result, 
age per se is not an independent contributor to 
CD28null T-cell expansion in the CD8 compartment 
either. Of note, the median frequencies of CD28null 
CD8 T-cells in CMV− participants were on the order 
of 25%, i.e., about two orders of magnitude higher 
than the median CD28null CD4 T-cell frequencies. 
These constitutionally high levels suggest that 
CD28null CD8 T-cells are involved in the recognition of 
multiple antigens, which might explain their 
functional heterogeneity [22]. In CMV+ individuals, 
their frequencies were ‘only’ about twice as high as 
those of CMV− individuals. The effect of CMV on 
CD28null T-cell accumulation in the CD8 T-cell 
compartment was, therefore, much smaller than in the 
CD4 T-cell compartment.  
Recently, the identification of CMV as the most 
likely, main driver of premature heart disease in 
HIV+ individuals caused a significant paradigm shift 
[42, 43]. Robustly testing the effect of CMV infection 
in this situation required a large number of CMV− 
individuals. This was also true for understanding the 
role of CMV infection in the accumulation of CD28null 
CD4 T-cells in our study. Widespread overestimation 
of CMV prevalence in the aging population in the US 
and Western Europe might explain why the effect of 
CMV on CD28null CD4 T-cells was not more robustly 
investigated before [23]. 
Regarding other factors influencing the 
frequencies of CD28null CD4 T-cells, the discovery of a 
protective effect of HLA-DRB1*0301P against 
expansion of these cells was exciting, because a 
protective effect of HLA-DRB1*0301P was previously 
described with respect to severe disease in RA [39, 44]. 
In RA, CD28null CD4 T-cells were shown to correlate 
with disease severity and the extent of extra-articular 
damage [12, 27]. HLA-DRB1*0301P might present 
peptides inducing regulatory T-cells that 
subsequently inhibit CD28null CD4 T-cell expansions. 
General inflammation levels, however, seemed to 
have only a small effect on CD28null CD4 T-cells. In 
CMV+ individuals with increased CRP levels (> 5 
mg/L), CD28null CD4 T-cell frequencies were just 
slightly higher than in those with normal levels, 
whereas in CMV− individuals CRP had no noticeable 
effect.  
In agreement with previous studies [26, 27], our 
results demonstrate that many CD28null CD4 T-cells 
recognize CMV antigens. Since we tested responses 
against select CMV proteins only, the sizes of the 
measured responses (median 7%, maximum of 18%) 
will have grossly underestimated the true proportion 
of CMV-specific cells among CD28null CD4 T-cells. 
This is because CMV+ individuals with a large 
response to one CMV protein usually recognize 
multiple additional ones [35]. Due to the fact that a 
majority of CMV-reactive CD4 T-cells are CD28null, 
each additional response will account for additional 
CD28null CD4 T-cells. No published report 
conclusively shows that these cells recognize antigens 
other than CMV. However, cross-reactivity between 
CMV-antigens and the stress-induced protein, 
heat-shock protein 60 [45] exists at the antibody level. 
Cross-reactivity with stress-induced proteins, for 
example, should be explored for T-cells as well. In any 
event, the majority of CMV-specific CD4 T-cells have 
the aggressive, CD28null phenotype and high 
expression of the vascular adhesion molecule, CD49d, 
which probably makes them an exemplar of 
pro-atherogenic T-cells [29]. 
Conclusions 
Our study explains, at least in part, why CMV 
infection increases the risk of CVD-related death [1]. 
By inducing pro-atherogenic CD28null T-cells, as a 
direct response to CMV infection (CMV-specific 
CD28null CD4 T-cells), or indirectly, by mechanisms 
yet to be discovered, CMV drives immune 
cell-mediated vascular damage. This ‘collateral’ 
damage of CMV infection has been the 
(unrecognized) topic of many published papers 
dealing with CD28null CD4 T-cells and CVD and is a 
fascinating example of immunopathology. We must 
now start looking for ways to reduce CD28null CD4 
T-cells in CMV-infected older people at risk of 
cardiovascular complications. Simply treating CMV 
might have real potential to achieve this. For example, 
aciclovir was shown to dramatically reduce the 
frequencies of CMV-specific CD4 T-cells in older 
humans [46] and valaciclovir was shown to reduce 
CMV-specific T-cells in mice [47]. Attempting to 
reduce the frequencies of CD28null CD4 T-cells with 





these drugs in individuals at risk could be the next 
decisive step forward. However, in the long run, we 
may need to develop effective, targeted interventions 
earlier in life. Knowing all relevant target antigens of 
CD28null CD4 T-cells and their HLA-associations will 
be particularly useful for that purpose.  
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